Characteristics of patients
| ID . | Age at start of therapy (y) . | Age at evaluation (y) . | Sex . | Therapy . | Duration of therapy (y) . | ECV* . | Diastolic classification . |
|---|---|---|---|---|---|---|---|
| CCH01 | 2.3 | 11 | Male | Chronic transfusions, hydroxyurea | 8.9 | 0.29 | No diastolic dysfunction |
| CCH02 | 2.7 | 17 | Female | Chronic transfusions | 14.6 | 0.27 | No diastolic dysfunction |
| CCH03 | 1.7 | 8 | Male | Chronic transfusions, hydroxyurea | 6.6 | 0.26 | Inconclusive |
| CCH04 | 1.9 | 7 | Female | Chronic transfusions, hydroxyurea | 5.9 | 0.29 | No diastolic dysfunction |
| CCH05 | 1.1 | 7 | Male | Chronic transfusions | 6.5 | 0.34 | No diastolic dysfunction |
| CHL01 | 3 | 28 | Female | Chronic transfusions | 24.9 | 0.37 | No diastolic dysfunction |
| CHL02 | 3.4 | 24 | Female | Hydroxyurea | 20.9 | 0.28 | No diastolic dysfunction |
| CHL03 | 3.2 | 19 | Female | Chronic transfusions | 15.8 | 0.28 | No diastolic dysfunction |
| CHL04 | 4.5 | 22 | Female | Hydroxyurea | 17.4 | 0.28 | No diastolic dysfunction |
| CHL05 | 5.4 | 21 | Female | Chronic transfusions | 11.7 | 0.36 | Inconclusive |
| CHL06 | 5.5 | 23 | Female | Hydroxyurea | 17 | 0.33 | No diastolic dysfunction |
| CHL07 | 2.4 | 16 | Male | Hydroxyurea | 13.7 | 0.29 | No diastolic dysfunction |
| ID . | Age at start of therapy (y) . | Age at evaluation (y) . | Sex . | Therapy . | Duration of therapy (y) . | ECV* . | Diastolic classification . |
|---|---|---|---|---|---|---|---|
| CCH01 | 2.3 | 11 | Male | Chronic transfusions, hydroxyurea | 8.9 | 0.29 | No diastolic dysfunction |
| CCH02 | 2.7 | 17 | Female | Chronic transfusions | 14.6 | 0.27 | No diastolic dysfunction |
| CCH03 | 1.7 | 8 | Male | Chronic transfusions, hydroxyurea | 6.6 | 0.26 | Inconclusive |
| CCH04 | 1.9 | 7 | Female | Chronic transfusions, hydroxyurea | 5.9 | 0.29 | No diastolic dysfunction |
| CCH05 | 1.1 | 7 | Male | Chronic transfusions | 6.5 | 0.34 | No diastolic dysfunction |
| CHL01 | 3 | 28 | Female | Chronic transfusions | 24.9 | 0.37 | No diastolic dysfunction |
| CHL02 | 3.4 | 24 | Female | Hydroxyurea | 20.9 | 0.28 | No diastolic dysfunction |
| CHL03 | 3.2 | 19 | Female | Chronic transfusions | 15.8 | 0.28 | No diastolic dysfunction |
| CHL04 | 4.5 | 22 | Female | Hydroxyurea | 17.4 | 0.28 | No diastolic dysfunction |
| CHL05 | 5.4 | 21 | Female | Chronic transfusions | 11.7 | 0.36 | Inconclusive |
| CHL06 | 5.5 | 23 | Female | Hydroxyurea | 17 | 0.33 | No diastolic dysfunction |
| CHL07 | 2.4 | 16 | Male | Hydroxyurea | 13.7 | 0.29 | No diastolic dysfunction |
ECV for normal controls: 0.26 ± 0.02; ECV for patients with untreated SCA: 0.44 ± 0.08.